Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The litigation, Mazzarino v. ADMA Biologics, Inc., claims the biopharmaceutical firm engaged in channel stuffing and undisclosed related party transactions to inflate its financial performance. These allegations surfaced following a March 2026 report by Culper Research, which asserted that the company’s reported growth was a fiction maintained by extending payment terms to distributors. According to the complaint, ADMA Biologics would have faced a 3% revenue decline in 2025 without these practices.

Market reaction to the report was immediate. ADMA Biologics stock dropped more than 16% on March 24. A further decline of over 13% occurred after Cantor Fitzgerald downgraded the stock from Overweight to Neutral, citing investor concern over the company’s rebuttal. While ADMA Biologics publicly dismissed the short-seller report as speculative and inaccurate, the legal challenge now moves forward. Robbins Geller Rudman & Dowd LLP, the firm representing the plaintiffs, notes that investors with substantial losses may apply to lead the case, though participating in a potential recovery does not require serving as a lead plaintiff.